Autologous Hair Follicle-Derived Secretomes

Hair loss remains one of the most common concerns in aesthetic and dermatologic medicine, with androgenetic alopecia (AGA) representing the predominant diagnosis in both men and women.¹ As medical and surgical options continue to evolve, demand is increasing for treatments that are effective, minimally invasive, and associated with little to no downtime. Autologous hair follicle-derived secretomes (aHFS) may be positioned as an entry-level regenerative therapy, an adjunct to existing treatments, or a complement to surgical interventions. 

This emerging, nonsurgical therapy uses biologically active signaling molecules derived from a patient’s own hair follicles. By targeting the underlying scalp microenvironment rather than simply masking hair loss, this approach offers a novel and practical addition to the hair restoration armamentarium. 

MECHANISM OF ACTION

Mechanistically, aHFS is a cell-free biologic composed of growth factors, cytokines, extracellular matrix proteins, and extracellular vesicles, including exosomes, released by hair follicle cells. These components are integral to regulation of the hair cycle and maintenance of follicular health (Fayyad M, Fatehi A, Han D, et al. The regenerative potential of the hair follicle and its secretome: review with original data. Publication pending.)

In AGA, progressive follicular miniaturization is driven by several factors, including shortening of the anagen (or growth) phase, decreased perifollicular vascularity, and increased inflammatory and fibrotic signaling.² The design of aHFS is intended to counter these processes through multiple mechanisms. 

It promotes prolongation of the anagen phase, supports thicker and longer hair shafts, enhances local vascular support, and improves nutrient delivery to follicles.^2,3 In addition, it modulates inflammatory pathways and reduces fibrosis, helping restore a scalp environment more conducive to sustained hair growth.²

Because aHFS is autologous, the risk of an immunologic reaction is minimal. As a cell-free therapy, it also avoids the safety and regulatory concerns associated with live cell-based treatments. 

PATIENT SELECTION

Careful patient selection is essential for optimizing outcomes, as aHFS is best suited for individuals with early to moderate AGA who retain viable, miniaturizing hair follicles. In this population, the therapy can enhance follicular performance and may stabilize or reverse early miniaturization. 

The treatment is particularly appealing for patients seeking nonsurgical options, those who are intolerant of systemic therapies, or individuals looking to augment existing regimens. It may also be used as an adjunct in the perioperative setting for hair transplantation. Similarly, it can be used to fortify patients’ native hairs and optimize the donor area in anticipation of future surgeries—particularly among younger patients. 

Patients with advanced hair loss characterized by significant follicular depletion are less likely to benefit, because aHFS does not generate new follicles. Similarly, results may be limited in scarring alopecia. 

Figure 1. Stepwise overview of aHFS therapy, highlighting a minimally invasive, standardized clinical profile (Graphic courtesy of Dr. Craig Ziering and Dr. Selam Ogbalidet).

TREATMENT PROTOCOL 

The aHFS process begins with the collection of approximately 70 hair follicles, obtained either through a simple outpatient plucking procedure or during hair transplantation. The follicles are processed over approximately 2 months to produce the secretome, which is supplied in multiple treatment vials. 

Clinical administration follows a standardized protocol. A fractional laser is used to create controlled microchannels in the scalp, enhancing delivery and stimulating local blood flow. The secretome is then reconstituted, commonly with hyaluronic acid, and applied topically, followed by massage and adjunctive red-light therapy. 

The procedure typically requires less than 1 hour and involves minimal downtime. Patients are advised to avoid washing the scalp for 24 hours after treatment. 

Treatment intervals vary based on clinical presentation. A maintenance regimen of treatments every 3 months is common, with more frequent sessions initially in patients with active shedding. Visible improvement is generally observed within approximately 3 months. 

PATIENT EDUCATION AND EXPECTATION MANAGEMENT

Effective patient education is critical to achieving high satisfaction. Patients should understand that aHFS improves the function of existing hair follicles rather than creating new ones. 

Results are gradual, with early changes typically observed after several months. The treatment is most effective in areas of thinning hair rather than completely bald regions. Ongoing maintenance treatments are required to sustain results. 

Framing aHFS as part of a long-term hair management strategy is essential. Combination therapy with medical or procedural treatments may further enhance outcomes. Clear communication regarding expected timelines and realistic outcomes is key to patient satisfaction. 

PRACTICE INTEGRATION 

aHFS can be readily incorporated into an aesthetic or hair restoration practice. The workflow includes patient education consultation and assessment, follicle collection, and scheduled treatment sessions once the product is available. The clinical team can expect a 2-month interval from the collection appointment to delivery of the secretomes, and patients should be counseled appropriately. 

The procedure is minimally invasive, well tolerated, and easily standardized, allowing for efficient delegation to trained staff. The need for ongoing maintenance treatments supports long-term patient engagement and continuity of care. 

CLINICAL OUTCOMES

Although individual results vary, appropriately selected and treated patients may experience improvements in hair quality, density, and overall scalp health. 

CONCLUSION

Autologous hair follicle-derived secretome represents a promising addition to the spectrum of hair restoration therapies. By delivering biologically active signaling molecules, it targets key mechanisms underlying follicular dysfunction. 

With appropriate patient selection, standardized protocols, and clear expectation management, aHFS can be effectively integrated into clinical practice as a safe, personalized, and nonsurgical approach to hair loss management. 

1. Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021;20(12):3759-3781. doi: 10.1111/jocd.14537. Epub 2021 Nov 6.

2. Shimizu Y, Watanabe Y, Kadota Y, et al. Regenerative medicine strategies for hair growth and regeneration: a narrative review of the literature. Regen Ther. 2022;21:527-539. https://doi.org/10.1016/j.reth.2022.10.001

3. Trüeb RM. Further clinical evidence for the effect of IGF-1 on hair growth and alopecia. Skin Appendage Disord.2018;4(2):90-95. https://doi.org/10.1159/000485191